Quidel

News Release

Printer Friendly Version View printer-friendly version << Back
December 14, 1999 at 12:00 AM EST

Quidel Corporation is Exclusive Licensee for Patent Granted for Peptide to be Used in Managing Osteoporosis

Peptide Patent Expands Quidel's Technology to Become a
Leader in the Diagnosis and Management of Osteoporosis

SAN DIEGO, Dec. 14 /PRNewswire/ -- Quidel Corporation (Nasdaq: QDEL) announced today that a patent was granted on a helical peptide believed to be valuable in measuring bone resorption. The patent covers an immunoassy method for measuring this peptide derived from type I collagen. The peptide assay is part of the intellectual property acquired through Quidel's purchase of the Mountain View, CA-based Metra Biosystems earlier this year.

,p>"We are pleased to be granted this patent. It represents an important advancement for both the detection of bone loss and for monitoring the therapy of patients being treated for osteoporosis," said Andre de Bruin, Quidel vice chairman, president and chief executive officer. "We intend to continue investing in the development of intellectual property in bone health in order to expand our product line in this important, growing market."

Bones are living tissue containing a matrix of predominantly type I collagen fibers and the cells which produce and remodel them. Normally, these collagen fibers are repaired, remodeled, and replenished daily throughout our lives. Osteoporosis is a disease characterized by decreased bone mass and a corresponding increased risk for bone fracture. In this disease, type I collagen is degraded more quickly than it is produced and incorporated into new bone. The degradation fragments of collagen appear in the blood and urine of patients where they can be detected by immunoassay. The helical peptide shows utility both for the detection of excessive bone deterioration and for monitoring therapy of patients with osteoporosis. It is expected that such tools will become important adjuncts to the successful management of patients with osteoporosis and other diseases characterized by abnormal bone formation and resorption.

Quidel Corporation discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women's health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, Chlamydia and infectious mononucleosis. Quidel's products are sold to healthcare professionals for use in physician's offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information to enable rapid treatment and improve health outcomes, lower costs, and increase patient satisfaction.

This press release contains forward-looking statements regarding Quidel, its products and its future activities within the meaning of the federal securities laws. These forward-looking statements involve material risks and uncertainties. Many possible factors could affect the future results and performance of Quidel's products, such that actual results and performance may differ materially. If Quidel's products fail to perform as expected, or if there is lower consumer demand for these products than expected, Quidel's financial condition and operating results may be materially and adversely affected. Quidel's financial condition and operating results may also be materially and adversely affected by a number of other factors, including, without limitation, seasonality, adverse changes in competitive and economic conditions, actions by the Company's distributors, manufacturing and production delays or difficulties and adverse actions or delays in product reviews by the FDA. Please see the discussion of these and other factors in Quidel's annual reports on Form 10-K and subsequent quarterly reports on Form 10-Q. For more information, please visit Quidel's web site at http://www.quidel.com.

CONTACT:
Charles J. Cashion, Chief Financial Officer, 858-552-7962,
or Christa Cerciello, Investor Relations, 858-646-8031,
both of Quidel Corporation